Enzo Biochem, Inc. Announces Issuance of United States Patent for Advanced Nucleic Acid Hybridization Probe Technology for Cl...
August 05 2019 - 9:00AM
Business Wire
Transformative Development in Diagnostic
Testing, Drug Development and Academic Research Marketplace
Provides a Simple, Cost Effective and Scalable Process
New Probe Technology Advances Company’s
Ability to Offer Lower-Cost High-Performance Products and Services
in the Clinical Diagnostics Market
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and
therapeutics company, today announced the issuance of U.S. Patent
No. 10,323,272 entitled Nucleic Acid Probes for In Situ
Hybridization. The patent is related to a new probe technology
developed by Enzo and transformative methods of testing using the
probes, which allow for significantly more cost effective, simple
and scalable processes across the multi-billion dollar diagnostic
testing, drug development and academic research marketplace.
These new probes can be used to detect clinically relevant
genomic targets with high-sensitivity in cell samples and biopsy
tissue obtained from patients. Significantly, the new probe design
permits the detection of such targets without the disadvantages
encompassed in competing high-sensitivity methods such as nucleic
acid amplification-based detection and branched DNA (bDNA) probe
technologies, which can involve high cost, high complexity, time
consuming processes and disruptions of sample integrity.
Elazar Rabbani, Ph.D., CEO of Enzo stated: “This is a
transformative advance for Enzo and the industry. We are pleased to
receive a U.S. patent for this new probe technology as we rapidly
integrate it across our line of cytology and pathology products and
services. With its superior sensitivity, simplicity of
manufacturing and use, and superb performance in combination with
Enzo’s PolyView® line of detection reagents, we believe this new
probe design will further drive Enzo’s business in existing in situ
hybridization markets, such as HPV testing. We also believe it will
enable a whole new range of applications for Enzo and its customers
in the areas of tissue analysis, cancer diagnostics and liquid
biopsy, as well as drug development and basic research.”
The company is currently developing a next-generation, liquid
cytology, Pap testing product as part of its women’s health
platform, that employs the new probe technology for detecting genes
of human papilloma viruses (HPV-16 and HPV-18) associated with
cervical cancer. As the same viruses are also responsible for a
growing number of oral and anal cancers, in both women and men,
there may also be substantial further applications for these HPV
probes.
Dr. Rabbani continued: “Because of its high-sensitivity signal
amplification feature, we are also exploring non-in situ uses of
this new probe design for the direct detection and quantification
of nucleic acids of interest, including very low quantity targets
where previously only nucleic acid amplification based techniques
that copy the target, such as the Polymerase-mediated Chain
Reaction (PCR), were practical.”
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Except for historical information, the matters discussed in this
news release may be considered "forward-looking" statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements include declarations regarding the intent,
belief or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses which are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigation, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2018. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190805005086/en/
For: Enzo Biochem, Inc. Steve Anreder, 212-532-3232
steven.anreder@anreder.com or Michael Wachs, CEOcast,
Inc., 212-732-4300 mwachs@ceocast.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024